The latest announcement is out from Collplant Holdings ( (CLGN) ).
On February 24, 2025, CollPlant Biotechnologies announced the expansion of its distribution channels for its VergenixSTR product in Europe and Asia. The distribution agreements with companies in the Netherlands, Turkey, and India will extend the sales of VergenixSTR, a product designed for treating tendinopathy in various tendons. This strategic move aims to enhance CollPlant’s market presence in the medical device sector, particularly in orthopedics, by leveraging the expertise of new distributors in Benelux, Spain, Turkey, and India. The expansion is expected to strengthen CollPlant’s position in the regenerative medicine industry by widening the reach of its innovative treatment for tendon injuries.
More about Collplant Holdings
CollPlant Biotechnologies is a regenerative and aesthetic medicine company specializing in developing products based on non-animal-derived collagen for tissue regeneration and medical aesthetics. The company focuses on 3D bioprinting of tissues and organs, tissue repair, and medical aesthetics, using its proprietary rhCollagen technology.
YTD Price Performance: -8.92%
Average Trading Volume: 10,424
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $39.75M
Learn more about CLGN stock on TipRanks’ Stock Analysis page.